Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.

Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol. 2020 Feb 14; 26(6):598-613.

View in: PubMed

subject areas

Acetylation
Antineoplastic Agents
Cell Death
Chemotherapy, Adjuvant
Chromatin Assembly and Disassembly
DNA, Neoplasm
Histone Deacetylase 1
Histone Deacetylase Inhibitors
Humans
Stomach Neoplasms

authors with profiles

Hassan Ashktorab
Mudasir Rashid
Duane Smoot

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support